Potent antagonist for the vitamin D receptor: vitamin D analogues with simple side chain structure.
We previously reported that 22S-butyl-25,26,27-trinor-1alpha,24-dihydroxyvitamin D(3) 2 was a potent VDR antagonist. The X-ray crystal structure of the ligand binding domain of VDR complexed with 2 indicated that this ligand induces an extra cavity within the ligand-binding pocket. The structure also showed that the ligand forms only poor hydrophobic interactions with helix 12 of the protein. Here, to study the effects of the induction of the extra cavity and of insufficient interactions with helix 12 on antagonism, we designed and synthesized a series of vitamin D(3) analogues with or without a 22-alkyl substituent and evaluated their biological potency. We found that the 22-butyl analogues 3c and 5c act as full antagonists, the 22-ethyl analogues 3b, 4b, 5b, and 22-butyl analogue 4c act as partial agonists, and the others (3a, 4a, 5a, 6a, 6b, and 6c) act as full agonists for VDR. It is intriguing that 6c is a potent agonist for VDR, whereas its 26,27-dinor analogue 5c is a potent antagonist. Analogue 6c recruited coactivator SRC-1 well, but 5c did not. These results indicate that a combination of induction of the extra cavity and insufficient hydrophobic interactions with helix 12 is important for VDR antagonism in this class of ligands.
Sakamaki
Yuta
Y
Laboratory of Drug Design and Medicinal Chemistry, Showa Pharmaceutical University, Machida, Tokyo, Japan.
Inaba
Yuka
Y
Yoshimoto
Nobuko
N
Yamamoto
Keiko
K
D000818:Animals; D001665:Binding Sites; D001667:Binding, Competitive; D019556:COS Cells; D002522:Chlorocebus aethiops; D002762:Cholecalciferol / Q000031:analogs & derivatives* / Q000138:chemical synthesis* / Q000494:pharmacology; D006801:Humans; D057927:Hydrophobic and Hydrophilic Interactions; D008024:Ligands; D008958:Models, Molecular; D056920:Nuclear Receptor Coactivator 1 / Q000378:metabolism; D018167:Receptors, Calcitriol / Q000819:agonists / Q000037:antagonists & inhibitors* / Q000235:genetics; D011994:Recombinant Proteins / Q000819:agonists / Q000037:antagonists & inhibitors; D047488:Retinoid X Receptors / Q000378:metabolism; D013237:Stereoisomerism; D013329:Structure-Activity Relationship; D015533:Transcriptional Activation; D014815:Vitamins / Q000138:chemical synthesis* / Q000494:pharmacology
D008024:Ligands; D018167:Receptors, Calcitriol; D011994:Recombinant Proteins; D047488:Retinoid X Receptors; D014815:Vitamins; D002762:Cholecalciferol; D056920:Nuclear Receptor Coactivator 1